phase 2 study

phase 2 study

See Phase study.
References in periodicals archive ?
The company said, "Phase 2 Study for Oral PTH in osteoporosis: The overall design and registration requirements for the planned pivotal Phase 3 study have been largely defined following the input from the U.S.
The company has an ongoing Phase 2 study and is progressing towards initiating another three by the end of 2019.
M2 EQUITYBITES-May 14, 2019-Karolinska Development's portfolio company reports on phase 2 study of sevuparin in patients with sickle cell disease
Global Banking News-May 14, 2019-Karolinska Development's portfolio company reports on phase 2 study of sevuparin in patients with sickle cell disease
M2 PHARMA-May 14, 2019-Karolinska Development's portfolio company reports on phase 2 study of sevuparin in patients with sickle cell disease
A Phase 2 study of sarilumab in systemic juvenile arthritis is also expected to begin in 2018.
(NASDAQ: PSTI; TASE: PLTR), announced that in anticipation of initiating a Phase 2 study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), the company recently entered into a collaborative agreement with CPC Clinical Research (CPC) for services related to enrolling and sustaining clinical sites.
This single-center, open label Phase 2 study will enroll up to 45 newly diagnosed, previously untreated patients.
We are now focusing our efforts on the oral formulation of Endoxifen and are developing a modified-release oral tablet which is being tested in a Phase 1 study and that we plan to use in a Phase 2 study to reduce MBD.
M2 PHARMA-April 30, 2018-Neuraltus Pharmaceuticals Phase 2 Study of NP001 in ALS Fails to Meet Primary orSecondary Endpoints
According to the company, the requirement of only one Phase 3 study was confirmed at an End of Phase 2 meeting with the regulatory authorities, following a prior Phase 2 study showing bioequivalence between the freeze-dried and liquid-frozen formulations of IMVAMUNE.
Separately, a Phase 3 study of GS-5745 is ongoing in patients with gastric cancer, as well as a Phase 2 study in patients with gastric cancer in combination with nivolumab and additional Phase 2 studies in moderately to severely active Crohns disease, rheumatoid arthritis and cystic fibrosis.